Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (Olema Oncology, Nasdaq: OLMA) is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other endocrine-driven cancers. The news flow around OLMA reflects its active clinical development program, capital markets activity, and ongoing corporate updates.
Investors and followers of Olema’s news can expect frequent updates on its lead product candidate, palazestrant (OP-1250), an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) being evaluated in ER+/HER2- metastatic breast cancer. Company announcements include progress in pivotal Phase 3 trials such as OPERA-01 and OPERA-02, data presentations from Phase 1b/2 studies of palazestrant in combination with ribociclib, and details on additional Phase 1/2 combination studies with agents like palbociclib, alpelisib, everolimus, and atirmociclib.
Olema’s news stream also covers pipeline developments for OP-3136, a KAT6 inhibitor in Phase 1 clinical evaluation as monotherapy and in combination with fulvestrant and palazestrant in advanced solid tumors. Regulatory and collaboration milestones, such as clinical trial agreements with Pfizer to study palazestrant plus atirmociclib, are disclosed through press releases and SEC filings.
In addition, Olema regularly reports financial and operating results, underwritten public offerings of common stock under its shelf registration on Form S-3, and inducement grants of stock options to new employees under its 2022 Inducement Plan. The company also announces participation in healthcare and investor conferences, where it presents updates on its clinical programs and strategy. Readers who follow OLMA news gain insight into trial progress, collaboration agreements, financing activities, and other corporate events that shape Olema’s development as a clinical-stage oncology company.
Olema Pharmaceuticals has appointed Yi Larson to the Board of Directors amid advancements in its clinical development, particularly the OP-1250 program for breast cancer. Larson, previously CFO of Turning Point Therapeutics, brings extensive operational and healthcare banking experience. Frank McCormick, a longstanding director, transitions to Chair of the Scientific Advisory Board, continuing to advise Olema on its oncology strategies. This leadership shift aims to boost Olema's growth and pipeline expansion efforts focused on women’s cancers.
Olema Pharmaceuticals (NASDAQ: OLMA) reported significant progress in 2020, highlighted by the initiation of a Phase 1/2 clinical trial for OP-1250, targeting ER+/HER2- breast cancer. The company raised approximately $382 million from Series B, Series C, and its IPO. Cash and cash equivalents reached $338.5 million as of December 31, 2020, providing funding through 2022. However, net losses rose to $24.0 million for the year, up from $4.3 million in 2019. Research and development expenses increased significantly to $13.7 million, reflecting ongoing clinical efforts.
Olema Pharmaceuticals announced a poster presentation on OP-1250, an estrogen receptor antagonist and degrader for metastatic breast cancer, at the AACR Annual Meeting, virtually scheduled for April 10-15, 2021. The late-breaking abstract, accepted by AACR, highlights OP-1250's potential in shrinking ER+ brain metastases in a model expressing mutant ESR1. Olema's ongoing Phase 1/2 clinical trial evaluates OP-1250 as a treatment for ER+/HER2- breast cancer. The presentation aims to elevate awareness and interest in the drug's application in women's cancers.
Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company, will participate in two upcoming virtual investor conferences. On March 2, 2021, CEO Sean P. Bohen will join a breast cancer panel at the Cowen 41st Annual Health Care Conference. Following that, on March 15, 2021, he will participate in a women's health panel at the 33rd Annual ROTH Growth Conference. Olema focuses on targeted therapies for women’s cancers, with its lead product OP-1250 currently undergoing a Phase 1/2 trial for ER-positive breast cancer.
Olema Pharmaceuticals (NASDAQ: OLMA) announced that its CEO, Sean P. Bohen, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 11, 2021, at 10 a.m. ET. The presentation will be available for live streaming, and a replay will be provided thereafter. Olema is focused on developing targeted therapies for women's cancers, with its lead candidate, OP-1250, being evaluated for ER-positive breast cancer in a Phase 1/2 trial.
Olema Pharmaceuticals has announced two poster presentations regarding OP-1250, an innovative estrogen receptor antagonist and selective ER degrader, at the virtual San Antonio Breast Cancer Symposium. The studies focus on OP-1250's efficacy in shrinking tumors in preclinical xenograft models and a Phase 1/2 clinical trial protocol for patients with advanced HR-positive, HER2-negative breast cancer. Presentations are scheduled for December 9, 2020, showcasing Olema's commitment to advancing targeted therapies for women's cancers.
Olema Pharmaceuticals has successfully closed its initial public offering (IPO) of 12,650,000 shares at $19.00 per share, raising approximately $240.4 million. This includes 1,650,000 shares sold due to the underwriters' full exercise of their option. The shares began trading on Nasdaq under the ticker symbol 'OLMA' on November 19, 2020. The offering was managed by J.P. Morgan, Jefferies, and Cowen, with registration statements becoming effective on November 18, 2020.
Olema Pharmaceuticals, Inc. has announced the pricing of its initial public offering of 11,000,000 shares at $19.00 per share, aiming to raise approximately $209.0 million before expenses. All shares are being offered by Olema, which has also given underwriters a 30-day option for an additional 1,650,000 shares. The shares are set to trade on the Nasdaq under the ticker symbol OLMA, starting November 19, 2020, with the offering expected to close on November 23, 2020. J.P. Morgan, Jefferies, and Cowen are leading the offering.